CompletedNot Applicable

Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis

China26 participantsStarted 2016-11-01

Plain-language summary

Plasma midkine has reported to be elevated in infection and a regulator of angiotensin-converting enzyme (ACE). We aimed to investigate the plasma midkine in septic patients and its association with 28-day mortality and organ function, and also with plasma ACE and angiotensin II.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

The inclusive criteria were adult patients (age \> 18 years-old and \< 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016) Exclusive criteria included: 1. age \< 18 years-old or \> 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.

What they're measuring

28-day mortality

Timeframe: up to 28 days

Trial details

NCT IDNCT02605681

SponsorSoutheast University, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-03-31

View on ClinicalTrials.gov More Sepsis trials